NEW YORK, June 4, 2019 /PRNewswire/ -- Bernstein Liebhard
LLP, a nationally acclaimed investor rights law firm, announced
that a securities class action lawsuit has been filed on behalf of
those who purchased or acquired the securities of Heron
Therapeutics, Inc. ("Heron," "HRTX" or the "Company") (NASDAQ:
HRTX) between October 31, 2018 and
April 30, 2019, both dates inclusive
(the "Class Period"). The lawsuit, filed in the United States District Court for the
Southern District of California,
seeks to recover damages for Heron investors under the Securities
Exchange Act of 1934.
If you purchased HRTX securities, and/or would like to
discuss your legal rights and options, please visit Heron
Therapeutics HRTX Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877)
779-1414 or MGuarnero@bernlieb.com.
According to the lawsuit, throughout the Class Period,
Defendants made materially false and/or misleading statements, as
well as failed to disclose material adverse facts about the
Company's business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose that: (i) Heron had failed to include adequate Chemistry,
Manufacturing, and Controls ("CMC") and non-clinical information in
its new drug application ("NDA") for HTX-011, a drug for management
of post-operative pain; (ii) the foregoing increased the likelihood
that the Food and Drug Administration ("FDA") would not approve
Heron's NDA for HTX-011; and (iii) as a result, Heron's public
statements were materially false and misleading at all relevant
times.
On May 1, 2019, Heron announced
that it had received a Complete Response Letter ("CRL") from the
FDA on April 30, 2019 regarding the
Company's NDA for HTX-011. Heron advised investors that
"[t]he CRL stated that the FDA is unable to approve the NDA in its
present form based on the need for additional CMC and non-clinical
information."
On this news Heron's stock price fell $3.93 per share, or 18.13% to close at
$17.75 per share on May 1, 2019.
If you wish to serve as lead plaintiff in the Heron class
action, you must move the court no later than August 5, 2019. A lead plaintiff is a
representative party acting on behalf of other class members in
directing the litigation. Your ability to share in any recovery
doesn't require that you serve as lead plaintiff. If you take no
action, you may remain an absent class member.
If you purchased Heron securities, and/or would like to
discuss your legal rights and options, please visit
https://www.bernlieb.com/cases/heron-therapeutics-hrtx-shareholder-lawsuit-class-action-fraud-stock-138/or
contact Matthew E. Guarnero toll
free at (877) 779-1414 or MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over
$3.5 billion for its clients. In
addition to representing individual investors, the Firm has been
retained by some of the largest public and private pension funds in
the country to monitor their assets and pursue litigation on their
behalf. As a result of its success litigating hundreds of lawsuits
and class actions, the Firm has been named to The National
Law Journal's "Plaintiffs' Hot List" thirteen times and
listed in The Legal 500 for ten consecutive
years.
ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hrtx-class-action-alert-bernstein-liebhard-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-heron-therapeutics-inc--hrtx-300861725.html
SOURCE Bernstein Liebhard LLP